Aurinia Pharmaceuticals Inc (AUPH NASDAQ) stock market data APIs
$12.3459
0.38(3.1%)
as of September 17, 2025
Try our APIs with
free plan!
Aurinia Pharmaceuticals Inc Financial Data Overview
Price chart is built with
Anychart
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company that engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs. It offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. The company also develops AUR200, a dual inhibitor of B cell activating factor and a proliferation inducing ligand for the potential treatment of autoimmune diseases. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.
Prev. Close
12.3459
Open
12.726
High
12.6325
Low
12.1232
52 wk Range
6.55-12.9
Market Cap
1 619 M
P/E Ratio
28.6047
Shares Outstanding
132 M
Revenue
260 M
EPS
0.16
Beta
1.271
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Aurinia Pharmaceuticals Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Aurinia Pharmaceuticals Inc data using free add-ons & libraries
Get Aurinia Pharmaceuticals Inc Fundamental Data
Aurinia Pharmaceuticals Inc Fundamental data includes:
- Net Revenue: 260 M
- EBITDA: 82 582 K
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-07-31
- EPS/Forecast: 0.14
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Aurinia Pharmaceuticals Inc News
New
Oric Pharmaceuticals Stock Scores RS Rating Upgrade
Oric Pharmaceuticals stock had its Relative Strength (RS) Rating upgraded from 80 to 83 Wednesday. Looking For The Best Stocks To Buy And Watch? Start Here IBD's proprietary rating tracks share price movement with a 1 (worst) to 99 (best) score. Continue Reading View Comments
7 Biotech Stocks Trading At 52-Week Highs - Can The Rally Continue?
(RTTNews) - Patience is a virtue - important in all aspects of life, and especially crucial when it comes to investing. As trading expert Steve Burns once said, "Much of our trading comes down to a ba...
Dianthus Therapeutics Stock Earns RS Rating Upgrade
On Monday, Dianthus Therapeutics stock hit an important technical milestone, with its Relative Strength (RS) Rating climbing into the 80-plus percentile with an upgrade to 81, an increase from 74 the ...
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Shows Strong Growth Metrics and Earnings Momentum
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH [https://www.chartmill.com/stock/quote/AUPH]) has become an interesting candidate for growth investors using the screening method from Louis Navellier's "The L...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
